by ActiGraph PENSACOLA, FL, February 20, 2024 – ActiGraph and Cambridge Cognition, leading providers of wearable digital health technologies and CNS assessments, respectively, announced a new strategic partnership to deliver a broad suite of assessments to provide a fully-rounded view of mental and physical capabilities. The companies’ technologies have been used together by top 20 […]
Cambridge Cognition unveils strategic partnership for Chinese market expansion Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare
Cambridge Cognition’s Global Teams Unite for Mental Health Causes! Read More »
News Back to resource centre 24 October 2023 Launch of automated quality assurance for clinical trials Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the launch today of AQUA, the Company’s automated quality assurance solution for central nervous system (“CNS”) clinical trials that is powered
Launch of automated quality assurance for clinical trials Read More »
Cambridge Cognition unveils strategic partnership for Chinese market expansion Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare
2023 CANTAB Research Grant winners announced Read More »
News Back to resource centre 24 November 2022 Cambridge Cognition unveils strategic partnership for Chinese market expansion Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare
Cambridge Cognition’s Global Teams Unite for Mental Health Causes! Read More »
News Back to resource centre 11 January 2023 Cambridge Cognition and Winterlight Labs join forces to lead in voice and digital biomarkers for clinical trials Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce its acquisition of Winterlight, a leader in monitoring cognitive impairment through free-speech analysis.Both Cambridge Cognition and Winterlight share a
News Back to resource centre 24 November 2022 Cambridge Cognition unveils strategic partnership for Chinese market expansion Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare
Cambridge Cognition unveils strategic partnership for Chinese market expansion Read More »
News Back to resource centre 12 October 2022 Cambridge Cognition strengthens virtual clinical trials offering with eClinicalHealth acquisition Cambridge Cognition has entered an agreement to acquire eClinicalHealth Ltd; a full-service digital technology provider that is working on virtual clinical trials for three of the world’s top ten largest pharmaceutical companies.Catalysed by the pandemic, the overall virtual clinical trials market has
News Back to resource centre 12 October 2022 Cambridge Cognition strengthens virtual clinical trials offering with eClinicalHealth acquisition Cambridge Cognition has entered an agreement to acquire eClinicalHealth Ltd; a full-service digital technology provider that is working on virtual clinical trials for three of the world’s top ten largest pharmaceutical companies.Catalysed by the pandemic, the overall virtual clinical trials market has
News Back to resource centre 17 August 2022 Cambridge Cognition selected by the University of Oxford as a cognitive assessment partner for the ISAP study Alzheimer’s disease validation for NeuroVocalixTMCambridge Cognition is pleased to announce that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid Positivity (“ISAP”) study. As
